Neon Therapeutics Vaccine Study Shows Prolonged Progression-Free Survival
15 Juli 2019 - 03:04PM
Dow Jones News
By Colin Kellaher
Neon Therapeutics Inc. (NTGN) on Monday said a phase 1b study of
NEO-PV-01, its personal neoantigen vaccine candidate, showed
prolonged and consistent improvements in progression-free survival
in three distinct tumor types.
The Cambridge, Mass., clinical-stage immuno-oncology company
said NEO-PV-01 in combination with Bristol-Myers Squibb Co.'s (BMY)
cancer drug Opdivo improved progression-free survival in patients
with advanced or metastatic melanoma, smoking-associated non-small
cell lung cancer, and bladder cancer.
Neon said the study data support future randomized phase 2
development of NEO-PV-01, a vaccine that is custom-designed for
each individual patient and intended to generate an anti-tumor
immune response directing T cells to target particular neoantigens
in the patient's tumor.
Shares of Neon, which closed Friday at $4.32, rose 13.4% in
premarket trading Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 15, 2019 08:49 ET (12:49 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
Von Mär 2023 bis Mär 2024